Farmacia
Facultad
AstraZeneca (United Kingdom)
Cambridge, Reino UnidoPublicaciones en colaboración con investigadores/as de AstraZeneca (United Kingdom) (13)
2021
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
The Lancet, Vol. 397, Núm. 10269, pp. 99-111
-
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
The Lancet, Vol. 397, Núm. 10277, pp. 881-891
2020
-
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
The Lancet, Vol. 396, Núm. 10267, pp. 1979-1993
2019
-
Preclinical evaluation of AZ12601011 and AZ12799734, inhibitors of transforming growth factor B superfamily type 1 receptors
Molecular Pharmacology, Vol. 95, Núm. 2, pp. 222-234
2017
-
A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts
Leukemia Research, Vol. 56, pp. 82-87
-
Inhibition of T-Cell activation by the CTLA4-Fc abatacept is sufficient to ameliorate proteinuric kidney disease
American Journal of Physiology - Renal Physiology, Vol. 312, Núm. 4, pp. F748-F759
-
Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia
British Journal of Cancer, Vol. 117, Núm. 2, pp. 256-265
-
Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia
Journal of Hematology and Oncology, Vol. 10, Núm. 1
2015
-
A low frequency of losses in 11q chromosome is associated with better outcome and lower rate of genomic mutations in patients with chronic lymphocytic leukemia
PLoS ONE, Vol. 10, Núm. 12
-
In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates
International Journal of Antimicrobial Agents, Vol. 45, Núm. 6, pp. 641-646
2009
-
A global benchmark study using affinity-based biosensors
Analytical Biochemistry, Vol. 386, Núm. 2, pp. 194-216
1994
-
Inhibitory activity of a series of coumarins on leukocyte eicosanoid generation
Agents and Actions, Vol. 42, Núm. 1-2, pp. 44-49